title: Angiotensin-converting enzyme inhibitors prevent LDL-induced endothelial dysfunction by reduction of asymmetric dimethylarginine level.
authors.forename: Jun-Lin
authors.initials: JL
authors.lastname: Jiang
authors.forename: Hui-Qing
authors.initials: HQ
authors.lastname: Zhu
authors.forename: Zhou
authors.initials: Z
authors.lastname: Chen
authors.forename: Hai-Yuan
authors.initials: HY
authors.lastname: Xu
authors.forename: Yuan-Jian
authors.initials: YJ
authors.lastname: Li
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology*; D008078:Cholesterol, LDL / Q000008:administration & dosage / Q000187:drug effects*; D004656:Enalapril / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D023421:Models, Animal; D051381:Rats
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D008078:Cholesterol, LDL; C487735:dimethylarginine; D004656:Enalapril; D001120:Arginine; D002216:Captopril